Neumora Therapeutics, Inc.

NMRA

$307M

Small Cap

NASDAQBiotechnology🇺🇸North America95 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
NMRA-335140	Phase 3	Major Depressive Disorder	-
Placebo	Phase 3	Major Depressive Disorder	-
NMRA-335140 80 mg	Phase 2	Major Depressive Episode Associated With Bipolar II Disorder	-

Catalyst Timeline

3 upcoming, 0 past

⭐Phase 3Next

February 2026~Placebo

Primary completion for Placebo trial (NCT06058039) in Major Depressive Disorder

⭐Phase 3

February 2026~NMRA-335140

Primary completion for NMRA-335140 trial (NCT06058039) in Major Depressive Disorder